Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 2.47 is 87% below its 5-year average of 18.88, near the low end of its 5-year range (2.47–137.62).
As of the fiscal period ended Tuesday, June 30, 2026. 46.59% below its 12-month average of 4.62.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.47.
QUICK RATIO (ACID-TEST)
2.47
QUICK RATIO (ACID-TEST) AVG TTM
4.62
QUICK RATIO (ACID-TEST) AVG 3Y
10.98
QUICK RATIO (ACID-TEST) AVG 5Y
18.88
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-46.59%
CURRENT VS 3Y AVG
-77.55%
CURRENT VS 5Y AVG
-86.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
-26.40%
vs the sector median at left
Acumen Pharmaceuticals, Inc.
Market Cap
$146.98M
Quick Ratio (Acid-Test)
2.47
TTM Avg
4.62
3Y Avg
10.98
5Y Avg
18.88
Market Cap
$148.33M
Quick Ratio (Acid-Test)
7.51
TTM Avg
6.60
3Y Avg
4.97
5Y Avg
4.99
Market Cap
$148.36M
Quick Ratio (Acid-Test)
1.23
TTM Avg
1.14
3Y Avg
1.35
5Y Avg
4.96
Market Cap
$148.57M
Quick Ratio (Acid-Test)
15.62
TTM Avg
10.23
3Y Avg
11.93
5Y Avg
11.24
Market Cap
$148.69M
Quick Ratio (Acid-Test)
9.71
TTM Avg
4.67
3Y Avg
6.04
5Y Avg
19.74
Market Cap
$149.14M
Quick Ratio (Acid-Test)
2.99
TTM Avg
3.92
3Y Avg
3.42
5Y Avg
4.30
Market Cap
$149.28M
Quick Ratio (Acid-Test)
5.55
TTM Avg
4.34
3Y Avg
4.83
5Y Avg
5.44
Market Cap
$149.89M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$144.05M
Quick Ratio (Acid-Test)
0.82
TTM Avg
5.49
3Y Avg
4.19
5Y Avg
4.19
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $146.98M | 2.47 | 4.62 | 10.98 | 18.88 |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.33M | 7.51 | 6.60 | 4.97 | 4.99 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | 1.23 | 1.14 | 1.35 | 4.96 |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.57M | 15.62 | 10.23 | 11.93 | 11.24 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.69M | 9.71 | 4.67 | 6.04 | 19.74 |
| Codexis, Inc. (CDXS)vs › | $149.14M | 2.99 | 3.92 | 3.42 | 4.30 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $149.28M | 5.55 | 4.34 | 4.83 | 5.44 |
| Veraxa Biotech Holding AG (VRXA)vs › | $149.89M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.05M | 0.82 | 5.49 | 4.19 | 4.19 |
| Nyxoah S.A. (NYXH)vs › | $143.10M | 2.31 | 2.75 | 4.17 | 7.24 |
Quick Ratio
2.47
Excludes inventory
Current Ratio
2.47
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 2.47 |
| 2026-03-31 | 4.55 |
| 2025-12-31 | 4.07 |
| 2025-09-30 | 6.02 |
| 2025-06-30 | 5.97 |
| 2025-03-31 | 8.02 |
| 2024-12-31 | 6.45 |
| 2024-09-30 | 10.42 |
| 2024-06-30 | 17.37 |
| 2024-03-31 | 30.20 |
| 2023-12-31 | 19.01 |
| 2023-09-30 | 35.84 |
| 2023-06-30 | 17.21 |
| 2023-03-31 | 16.25 |
| 2022-12-31 | 23.06 |
| 2022-09-30 | 30.60 |
| 2022-06-30 | 37.19 |
| 2022-03-31 | 48.72 |
| 2021-12-31 | 38.60 |
| 2021-09-30 | 137.62 |
| 2021-06-30 | 15.62 |
| 2021-03-31 | 1.35 |
| 2020-12-31 | 6.98 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
